SP
GLUE icon

Sarasin & Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Sarasin & Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-65,081
Closed -$243K – 84
2024
Q2 		$243K Hold
65,081
– – ﹤0.01% 83
2024
Q1 		$459K Hold
65,081
– – ﹤0.01% 80
2023
Q4 		$368K Hold
65,081
– – ﹤0.01% 84
2023
Q3 		$312K Hold
65,081
– – ﹤0.01% 79
2023
Q2 		$446K Hold
65,081
– – 0.01% 81
2023
Q1 		$507K Hold
65,081
– – ﹤0.01% 101
2022
Q4 		$495K Hold
65,081
– – 0.01% 90
2022
Q3 		$532K Hold
65,081
– – 0.01% 89
2022
Q2 		$629K Buy
+65,081
New +$654K 0.01% 88

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Sarasin & Partners's GLUE Position: Q3 2024 in Review

Sarasin & Partners sold out of Monte Rosa Therapeutics (GLUE) in Q3 2024, closing a stake of 65,081 shares — an estimated $243K sold.

Sarasin & Partners first reported a position in GLUE in Q2 2022 and held it in 9 quarters. The position peaked at $629K in Q2 2022. 81 funds tracked by Wall St. Rank hold GLUE as of Q3 2024.

  • Sarasin & Partners reported no remaining Monte Rosa Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sarasin & Partners sold 65,081 Monte Rosa Therapeutics shares in Q3 2024, an estimated $243K.
  • Sarasin & Partners first reported a position in Monte Rosa Therapeutics in Q2 2022 and held it in 9 quarters.
  • Sarasin & Partners's Monte Rosa Therapeutics position peaked at $629K in Q2 2022.
  • 81 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2024.

Based on Sarasin & Partners's 13F filing for Q3 2024, filed 9 Oct 2024.